FEB 19, 2014 10:00 AM PST

Next-generation sequencing applications in advanced cancer samples: Experience with Ion AmpliSeq custom panels

Speakers
  • Medical Director of Knight Diagnostic Laboratories Director of Molecular Pathology, Oregon Health & Science University
    Biography
       
      After undergraduate studies at the Univ. of California, Berkeley, Professor Corless received his MD and PhD degrees from Washington University, St. Louis. He did his residency training in Anatomic Pathology at the Brigham & Women's Hospital, Boston, where he also completed fellowship training in GI Pathology and GU Pathology. In 1994, he joined the faculty of Oregon Health & Science University as an Assistant Professor. He has served as the residency program director in Pathology and medical director of surgical pathology for OHSU Hospital. He is an Associate Director of the Oregon Clinical & Translational Research Institute, and he presently serves as Chief Medical Officer for the OHSU Knight Diagnostic Laboratories. In addition to practicing surgical pathology, Dr. Corless has expertise in the application of molecular diagnostics to the classification and prognostication of solid tumors. He was promoted to Professor of Pathology in 2004 and is an author on over 200 publications.
       

    Abstract:
    Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are inadequate in the face of the rapidly growing list of genetic mutations that are potentially actionable. This presentation will focus on our experience in designing and running custom Ion AmpliSeq cancer gene panels on the Ion PGM System, an approach we are using to increase the understanding of genetic mutations in advanced cancers. Consideration will be given to detecting mutations of various types, as well as alterations in gene copy number. Critical pre-analytic factors and the integration of other technologies that define clinically significant targets
    for future treatment will also be discussed.

    Show Resources
    You May Also Like
    AUG 16, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 16, 2018 08:00 AM PDT
    DATE: August, 16, 2018TIME: 08:00AM PDTThis webinar will review recent advancements in the application of next-generation sequencing of T cell receptor beta (TCRB) chain repertoires towards...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    JUN 05, 2018 06:30 AM PDT
    C.E. CREDITS
    JUN 05, 2018 06:30 AM PDT
    DATE: June 5, 2018TIME: 06:30AM PDT, 3:30PM CEST Viscous liquids are a challenge in every lab that deals with them. Depending on how viscous a liquid is, pipetting is either...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    Loading Comments...